Key Summary Points {#FPar1}
==================

***Why carry out this study?***Patients with eosinophilic asthma can have elevated serum IgE concentrationsEosinophilia is associated with asthma exacerbations, which can be reduced with benralizumab, an interleukin-5 receptor alpha--directed anti-eosinophil monoclonal antibodyWe aimed to determine the importance of elevated blood eosinophil counts and serum IgE concentrations on exacerbation risk and their influence on benralizumab's ability to reduce exacerbation frequency for patients with eosinophilic asthma and a range of serum IgE concentrations***What was learned from the study?***Elevated blood eosinophil counts, but not serum IgE concentrations, are associated with increased exacerbation risk for patients with severe, uncontrolled asthmaBenralizumab reduces exacerbation risk for patients with elevated blood eosinophil counts regardless of serum IgE concentrations and, therefore, should be considered for patients with uncontrolled eosinophilic asthma with allergic characteristics

Introduction {#Sec1}
============

Asthma is a heterogenous disease that affects more than 339 million people worldwide \[[@CR1]--[@CR3]\]. Allergic asthma is a common phenotype of asthma, and several factors such as elevated immunoglobulin E (IgE) concentrations and eosinophilia play an important role in the pathology of this disease \[[@CR2]--[@CR5]\]. A total of 47% of adults have both eosinophilic (\> 150 cells/μL) and atopic asthma (with elevated IgE concentrations), while 78% of adults with atopic asthma also have eosinophilic asthma \[[@CR5]\]. It is, therefore, important to identify the characteristics of individual patients with severe asthma to determine the optimal treatment regimen.

Omalizumab (Genentech, Inc., South San Francisco, CA, USA), a humanized anti-IgE monoclonal antibody, is approved as add-on therapy for patients aged 6 years or older with moderate to severe persistent, uncontrolled asthma with positive skin test or in vitro reactivity to a perennial aeroallergen \[[@CR6]\]. In the phase III EXTRA clinical trial, omalizumab reduced exacerbation rates relative to placebo by 25% for patients with severe allergic asthma \[[@CR7]\]. In a post hoc analysis of this study, patients with allergic asthma and blood eosinophil counts ≥ 260 cells/µL had a 32% reduction in asthma exacerbation rate with omalizumab relative to placebo, compared with a 9% reduction for patients with blood eosinophil counts \< 260 cells/µL \[[@CR8]\]. Exacerbation rate reductions with omalizumab were similar regardless of serum IgE concentrations \[[@CR9], [@CR10]\].

Benralizumab (AstraZeneca, Cambridge, UK) is an interleukin-5 receptor alpha--directed cytolytic monoclonal antibody that induces direct, rapid, and nearly complete depletion of eosinophils via enhanced antibody-dependent cell-mediated cytotoxicity \[[@CR11], [@CR12]\]. Benralizumab 30 mg every 8 weeks (Q8W; first three doses every 4 weeks \[Q4W\]) is indicated for the add-on maintenance treatment of patients with severe asthma aged 12 years and older, and with an eosinophilic phenotype \[[@CR13]\]. In the 48-week SIROCCO and 56-week CALIMA phase III studies, significant reductions in annual asthma exacerbation rates (AERs) by 51% (*p* \< 0.0001) and 28% (*p* = 0.0188), respectively, were achieved with benralizumab Q8W compared with placebo for patients with severe, uncontrolled asthma and baseline blood eosinophil counts ≥ 300 cells/μL \[[@CR14], [@CR15]\]. In addition, significant improvements were also achieved with benralizumab Q8W relative to placebo in prebronchodilator forced expiratory volume in 1 s (FEV~1~) (0.159 L \[*p* = 0.0006\] and 0.116 L \[*p* = 0.0102\], respectively) at the end of treatment (EOT) \[[@CR14], [@CR15]\].

Benralizumab Q8W has also been demonstrated to reduce exacerbations and improve lung function for patients with severe, uncontrolled asthma with blood eosinophil counts ≥ 300 cells/µL and with either high serum IgE concentrations (≥ 150 kU/L; 53% of patients) or low serum IgE concentrations (\< 150 kU/L; 47% of patients), with or without atopy (based on Phadiatop \[Phadia AB/Thermo Fisher Scientific, Uppsala, Sweden\] test results), or for those who met the criteria similar to patients who might qualify for omalizumab treatment (serum IgE concentrations 30--700 kU/L and with atopy) or those who did not meet these criteria \[[@CR16]\]. AERs decreased by 42% (high serum IgE concentrations; *p* \< 0.0001), 43% (low serum IgE concentrations; *p* = 0.0004), 40% (with atopy; *p* \< 0.0001), 46% (without atopy; *p* = 0.0001), 46% (met criteria; *p* = 0.0002), and 39% (did not meet criteria; *p* \< 0.0001) with benralizumab Q8W relative to placebo \[[@CR16]\].

However, this dichotomous analysis has limitations, as it does not allow evaluation of differences in treatment effects across the full range of IgE concentrations. Unlike with blood eosinophil counts, there is lack of consensus on an IgE cut-off value that defines high vs. low concentrations. To address this and determine benralizumab efficacy for patients across a range of IgE concentrations, including very high, we categorized the study population into quartiles, an approach used to assess the effect of omalizumab on exacerbations \[[@CR10]\]. We analyzed pooled data from the SIROCCO and CALIMA studies to determine the influence of baseline blood eosinophil counts and serum IgE, across a range of concentrations, on exacerbation risk for patients with severe, uncontrolled asthma. Furthermore, as the influences of baseline blood eosinophil counts and serum IgE concentrations on exacerbation risk and benralizumab efficacy were previously studied independently, although variable concentrations of these biomarkers coexist for patients, we evaluated these two biomarkers together. We aimed to assess the potential utility of benralizumab for patients with eosinophilic asthma with allergic characteristics.

Methods {#Sec2}
=======

Study Design and Participants {#Sec3}
-----------------------------

SIROCCO and CALIMA were randomized, double-blind, parallel-group, placebo-controlled, international, phase III studies \[[@CR14], [@CR15]\]. The study designs consisted of an enrollment visit (week−4), a 4-week screening and run-in phase, randomization (week 0), treatment period from weeks 0 to 48 (SIROCCO) or 56 (CALIMA), and a final follow-up visit 8 weeks (SIROCCO) or 4 weeks (CALIMA) after the EOT period.

Enrollment criteria for the studies have been published \[[@CR14], [@CR15]\]. Male and female patients 12--75 years of age, weighing at least 40 kg, and with physician-diagnosed asthma that required treatment with medium- to high-dosage inhaled corticosteroids (ICS) and long-acting β~2~-agonists (LABA) for at least 12 months before enrollment were included. Patients had two or more asthma exacerbations within 12 months before the date of enrollment that required systemic corticosteroid therapy or a temporary increase in usual maintenance oral corticosteroid dosages \[[@CR14], [@CR15]\]. Before any patients enrolled, an independent ethics committee or institutional review board at each study center approved the clinical study protocol, and the national regulatory authority either approved the clinical study protocol or received a notification according to local regulations (see electronic supplementary materials). Studies were conducted in accordance with the Declaration of Helsinki, the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use and Good Clinical Practice guidelines, and the ethics committee at each participating site \[[@CR14], [@CR15]\]. All patients provided written informed consent at enrollment.

Treatments {#Sec4}
----------

In SIROCCO and CALIMA, patients were randomized 1:1:1 to receive placebo Q4W, benralizumab 30 mg subcutaneously Q4W, or benralizumab 30 mg subcutaneously Q8W (first three doses Q4W). Patients with baseline blood eosinophil counts ≥ 300 cells/μL and \< 300 cells/μL were recruited at a ratio of approximately 2:1, respectively.

Outcomes {#Sec5}
--------

In the present study, we performed analyses for patients who received placebo or the indicated benralizumab dosage (30 mg Q8W) in addition to high-dosage ICS and LABA (defined as fluticasone propionate ≥ 500 mg/day or equivalent total daily dosage) pooled from the SIROCCO and CALIMA studies.

AERs were determined as a function of baseline blood eosinophil counts or serum IgE concentrations, either separately or combined. An exacerbation was defined as asthma worsening that led to either systemic corticosteroid use (or temporary increase in a stable oral corticosteroid background dosage) for at least 3 days or a single depot-injectable dose of corticosteroid; an asthma-related emergency department or urgent care visit (duration \< 24 h) that required systemic corticosteroid use; or an asthma-related inpatient hospital admission (duration ≥ 24 h). Asthma worsening was defined as any new or increased symptoms or signs that were concerning to the patient or related to an asthma daily diary alert \[[@CR14], [@CR15]\].

Baseline blood eosinophil counts were evaluated as a continuous function, by categories prespecified in the SIROCCO and CALIMA studies (\< 150, ≥ 150 to \< 300, ≥ 300 to \< 450, and ≥ 450 cells/µL) and also for the SIROCCO and CALIMA primary population (≥ 300 cells/µL). Baseline serum IgE concentrations were evaluated as a continuous function or by quartiles (\< 62.0, ≥ 62.0 to \< 176.2, ≥ 176.2 to \< 453.4, and ≥ 453.4 kU/L). Evaluation of AERs as a function of serum IgE concentrations was also determined on the basis of baseline atopy status. Atopy was defined as a positive Phadiatop test reaction. The Phadiatop test is a multi-allergen inhalant screening blood test with extracts for house dust mites, cat and dog dander, mold spores, and tree, grass, and weed pollen.

Statistical Analysis {#Sec6}
--------------------

This analysis was performed for the full analysis set according to the intention-to-treat principle for the pooled SIROCCO and CALIMA studies. The full analysis set included all randomized patients who received any study treatment, regardless of their protocol adherence and continued participation in the study. The similarity of the SIROCCO and CALIMA studies allowed for their results to be pooled \[[@CR14], [@CR15]\]. Similarities included study design (the only difference being treatment period: 48 weeks for SIROCCO and 56 weeks for CALIMA), inclusion and exclusion criteria (except CALIMA included patients who used medium-dosage ICS), treatment, randomization, stratification, and outcomes. Included patients had similar baseline clinical characteristics across the trials. This permitted us to obtain more accurate estimates of the relationship of baseline blood eosinophil counts and serum IgE concentrations with AERs, both for placebo and for benralizumab relative to placebo. Analyses were performed with SAS 9.4 (SAS Institute, Cary, NC, USA).

We used locally weighted regression smoothing analysis with corresponding confidence intervals (CIs) to determine the relationship between AERs with blood eosinophil counts and serum IgE concentrations. We analyzed AERs and corresponding ratios via a negative binomial model, with adjustments for study, treatment, region, prior exacerbations, and oral corticosteroid use at time of randomization. The log of each patient's corresponding follow-up time was used as an offset variable in the model to adjust for different exposure times during which the events occurred. We determined the estimated treatment effect (i.e., rate ratio of benralizumab vs. placebo), corresponding CI, and two-sided *p* value for the rate ratio.

Results {#Sec7}
=======

Demographics and baseline clinical characteristics of SIROCCO and CALIMA patients were, in general, balanced between treatment groups overall \[[@CR14]--[@CR16]\].

There was a positive relationship between baseline blood eosinophil counts and AERs for patients in the placebo arm (with background high-dosage ICS/LABA) (Fig. [1](#Fig1){ref-type="fig"}). However, there was no relationship between increasing baseline serum IgE concentrations and AERs (Fig. [2](#Fig2){ref-type="fig"}). Baseline atopy status did not influence the relationship between baseline serum IgE concentrations and AERs (Fig. [3](#Fig3){ref-type="fig"}). Benralizumab reduced AERs for each of these patient populations, with greater benralizumab response with increasing blood eosinophil counts and consistent improvements with increasing serum IgE concentrations (Figs. [1](#Fig1){ref-type="fig"}, [2](#Fig2){ref-type="fig"}, [3](#Fig3){ref-type="fig"}).Fig. 1LOESS plot analysis of association between baseline blood eosinophil counts and exacerbation frequency (full analysis set). *CI* confidence interval, *LOESS* locally estimated scatterplot smoothing, *Q8W* every 8 weeks (first three doses every 4 weeks). Shaded areas represent 95% CI. Baseline blood eosinophil counts \> 1000 cells/µL are included in the model but not presented in the figureFig. 2LOESS plot analysis of association between baseline serum IgE concentrations and exacerbation frequency (full analysis set). *CI* confidence interval, *IgE* immunoglobulin E, *LOESS* locally estimated scatterplot smoothing, *Q8W* every 8 weeks (first three doses every 4 weeks). Shaded areas represent 95% CI. IgE concentrations \> 2000 kU/L are included in the model but not presented in the figureFig. 3LOESS plot analysis of association of baseline serum IgE concentrations and atopy status with exacerbation frequency (full analysis set). *CI* confidence interval, *IgE* immunoglobulin E, *LOESS* locally estimated scatterplot smoothing, *Q8W* every 8 weeks (first three doses every 4 weeks). Shaded areas represent 95% CI. IgE concentrations \> 2000 kU/L are included in the model but not presented in the figure

When we evaluated the relationship between blood eosinophil counts and serum IgE concentrations in combination, greater baseline blood eosinophil counts (i.e., ≥ 450 cells/µL) were associated with larger AERs than lesser baseline blood eosinophil counts (i.e., \< 150 cells/µL), regardless of baseline serum IgE concentrations (Table [1](#Tab1){ref-type="table"}) for patients receiving placebo. AERs increased with increasing baseline blood eosinophil count categories for most serum IgE concentration quartiles, although there was some variability. AERs were not greater in the fourth quartile of baseline serum IgE concentrations compared with the first quartile, and no obvious pattern in AER changes was observed with increasing baseline IgE concentrations across baseline blood eosinophil count categories.Table 1Effect of baseline blood eosinophil counts and serum IgE concentrations on annual asthma exacerbation rates for patients receiving placebo (full analysis set)Serum IgE concentration (kU/L)Crude AERBaseline blood eosinophil count (cells/µL)\< 150≥ 150 to \< 300≥ 300 to \< 450≥ 450 \< 62.01.25 (*n* = 53)0.91 (*n* = 57)1.28 (*n* = 32)1.44 (*n* = 43) ≥ 62.0 to \< 176.21.57 (*n* = 34)0.94 (*n* = 45)1.15 (*n* = 46)1.84 (*n* = 66) ≥ 176.2 to \< 453.41.10 (*n* = 30)1.93 (*n* = 42)1.19 (*n* = 45)1.38 (*n* = 80) ≥ 453.40.80 (*n* = 29)0.84 (*n* = 31)1.10 (*n* = 39)1.33 (*n* = 90)*AER* annual asthma exacerbation rate, *IgE* immunoglobulin E

Patients with eosinophilic asthma (≥ 300 cells/µL) treated with benralizumab had consistent decreases in AER relative to placebo regardless of baseline serum IgE concentration quartiles (Table [2](#Tab2){ref-type="table"}, Fig. [4](#Fig4){ref-type="fig"}). Rate ratios ranged from 0.47 (95% CI 0.31, 0.72; *p* = 0.0004) to 0.56 (95% CI 0.37, 0.84; *p* = 0.0057) across baseline serum IgE concentration quartiles (Table [2](#Tab2){ref-type="table"}).Table 2Annual asthma exacerbation rate reductions with benralizumab vs. placebo based on baseline serum IgE concentrations (full analysis set; baseline blood eosinophil counts ≥ 300 cells/µL)Serum IgE concentration (kU/L)PlaceboBenralizumab Q8W\< 62.0 Number of patients analyzed7573 Rate estimate (95% CI)1.40 (1.00, 1.96)0.71 (0.46, 1.09) Absolute difference estimate vs. placebo (95% CI)--− 0.69 (− 1.21, − 0.17) Rate ratio vs. placebo (95% CI)--0.51 (0.31, 0.84) Nominal *p* vs. placebo--0.0079≥ 62.0 to \< 176.2 Number of patients analyzed112109 Rate estimate (95% CI)1.66 (1.26, 2.18)0.79 (0.56, 1.10) Absolute difference estimate vs. placebo (95% CI)--− 0.87 (− 1.38, − 0.37) Rate ratio vs. placebo (95% CI)--0.47 (0.31, 0.72) Nominal *p* vs. placebo--0.0004≥ 176.2 to \< 453.4 Number of patients analyzed125106 Rate estimate (95% CI)1.37 (1.07, 1.76)0.71 (0.52, 0.97) Absolute difference estimate vs. placebo (95% CI)--− 0.67 (− 1.06, − 0.27) Rate ratio vs. placebo (95% CI)--0.52 (0.35, 0.76) Nominal *p* vs. placebo--0.0008≥ 453.4 Number of patients analyzed129128 Rate estimate (95% CI)1.22 (0.92, 1.62)0.68 (0.48, 0.96) Absolute difference estimate vs. placebo (95% CI)--− 0.54 (− 0.93, − 0.15) Rate ratio vs. placebo (95% CI)--0.56 (0.37, 0.84) Nominal *p* vs. placebo--0.0057Estimates were calculated via a negative binomial model, with adjustments for study, treatment, region, prior exacerbations, and oral corticosteroid use at time of randomization. The log of each patient's corresponding follow-up time was used as an offset variable in the model to adjust for different exposure times during which the events occurred*CI* confidence interval, *IgE* immunoglobulin E, *Q8W* every 8 weeks (first three doses every 4 weeks)Fig. 4Effect of baseline serum IgE concentrations on annual asthma exacerbation rate reduction with benralizumab vs. placebo (full analysis set; baseline blood eosinophil counts ≥ 300 cells/µL). CI confidence interval, IgE immunoglobulin E, Q quartile, Q8W every 8 weeks (first three doses every 4 weeks). Estimates were calculated via a negative binomial model, with adjustments for study, treatment, region, prior exacerbations, and oral corticosteroid use at time of randomization. The log of each patient's corresponding follow-up time was used as an offset variable in the model to adjust for different exposure times during which the events occurred. ^a^*p* \< 0.01

Discussion {#Sec8}
==========

IgE and eosinophils play distinct roles in the pathogenesis of allergic asthma \[[@CR4], [@CR17]\], although there is probably some overlap in these mechanisms because cross-linking of IgE also leads to increased eosinophil counts. IgE is associated with the acute and chronic phases of the disease. In the acute phase, allergens stimulate the production of IgE, and cross-linking of IgE promotes the inflammatory cascade associated with development of allergic asthma, leading to a significant increase in eosinophil counts in the chronic phase of the disease \[[@CR4], [@CR17]\]. The relevance of each component in the development and progression of allergic asthma symptoms, such as exacerbation frequency and reduced lung function, is unclear and may likely be different for each patient.

In this study, we evaluated the influence of baseline blood eosinophil counts and serum IgE concentrations on exacerbation frequency with a data set pooled from the phase III SIROCCO and CALIMA trials for benralizumab. While increasing baseline blood eosinophil counts were directly associated with greater AERs for patients receiving placebo at the end of the studies, baseline serum IgE concentrations had no influence on AERs. These results suggest that treatments that decrease eosinophils may reduce exacerbation frequency for patients with eosinophilic asthma with allergic characteristics, regardless of serum IgE concentrations. This conclusion was supported by our findings that benralizumab treatment resulted in substantial reductions in exacerbation rates for patients with severe, uncontrolled eosinophilic asthma regardless of serum IgE concentrations. These results expand on earlier findings that patients with blood eosinophil counts ≥ 300 cells/µL with either serum IgE concentrations ≥ 150 or \< 150 kU/L, with or without atopy, or who might or might not qualify for omalizumab treatment had substantial reductions (≥ 40%) in exacerbation frequencies \[[@CR16]\].

Omalizumab is an approved add-on treatment for patients with moderate to severe, uncontrolled allergic asthma with elevated serum IgE concentrations \[[@CR18]\]. Similar to findings for omalizumab \[[@CR9]\], baseline serum IgE concentrations do not predict benralizumab response. However, unlike omalizumab \[[@CR7], [@CR9]\], increasing baseline blood eosinophil counts are clearly associated with greater benralizumab efficacy. Overall, these studies suggest that omalizumab treatment may be efficacious for reducing symptoms of allergic asthma that are stimulated by the cross-linking of specific IgE in response to an allergic trigger. For patients with eosinophilic asthma with allergic characteristics, alternative treatments, such as benralizumab, may be needed.

Mepolizumab, a marketed human anti--interleukin-5 monoclonal antibody for patients with severe eosinophilic asthma \[[@CR19]\], has been evaluated in two separate studies for patients who either received \[[@CR20]\] or were qualified at study entry \[[@CR21]\] to receive omalizumab treatment. In a post hoc analysis of the phase III MENSA trial \[[@CR22]\], patients who received omalizumab had a 57% exacerbation rate reduction with mepolizumab vs. placebo (compared with 47% for those who did not receive omalizumab) \[[@CR20]\]. In a post hoc meta-analysis of data from the phase III MENSA \[[@CR22]\] and MUSCA \[[@CR23]\] trials, mepolizumab reduced exacerbation rates vs. placebo by 57% and 55% for patients who were qualified or unqualified for omalizumab (based on prescribing and dosing criteria), respectively \[[@CR21]\]. Together with our findings, this supports the use of agents that target eosinophils directly (benralizumab) or indirectly (mepolizumab) to reduce eosinophils for the treatment of patients with eosinophilic asthma with allergic characteristics.

A limitation of this study was the small numbers of patients for the different subgroups, which restricted interpretation of the findings with no consistent trends. Another limitation was that this post hoc analysis was not part of the general testing strategy. Because of this, all comparator results of benralizumab vs. placebo use nominal *p* values, and no formal statistical significance can be inferred. Lastly, this study was not performed for patients who were diagnosed with allergic asthma, and any association of improvements with benralizumab for this patient population is speculative.

Conclusions {#Sec9}
===========

Blood eosinophil counts, but not serum IgE concentration, predict exacerbation risk. Exacerbation rate reductions with benralizumab for patients with eosinophilia and elevated serum IgE concentrations and/or atopy indicate a potential benefit of benralizumab for patients with eosinophilic asthma with allergic characteristics. Physicians should consider eosinophil-depleting therapies for patients with uncontrolled asthma and elevated blood eosinophil counts, regardless of serum IgE concentrations.
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